We develop genetic medicines by engineering AAV capsids, regulatory elements and payloads to overcome current limitations in gene therapy.

Developing and leading business development, corporate strategy, competitive intelligence, and alliance management functions for public, clinical-stage nucleic acid therapeutic company in oncology and neuroscience.

Responsible for coordinating the investigation of strategic opportunities for in-licensing, co-development, co-promotion/co-marketing, and acquisitions. Our search and evaluation efforts cover assets across discovery, early clinical (Phase 1 and 2) and late clinical (Phase 2b and 3) development.

Led strategy and execution of medical affairs activities in the US and International divisions. Partial list of responsibilities included: defining annual and long-term strategy; field medical engagement; advisory board planning and execution; publication planning; Phase IV trial creation and oversight; reviewing investigator initiated studies; review and development of medical information letters and the global value and AMCP dossiers; implementing medical training for internal stakeholders; and managing a field medical team. Develop and maintain product and therapeutic knowledge in Women's Health, Medical Aesthetics, Medical Devices, and Oncology. Increasing responsibilities over time with three promotions (Senior Manager, Therapeutic Area Lead, Associate Director, and Director) in four years

We created a short and long-term investment strategy in the biotech/pharma sector. Demonstrating five-year annual returns of 34.4% and 21.1%, respectively

A new Canadian affiliate of a European company in Chronic Obstructive Pulmonary Disease (COPD). Developed expert knowledge in Respirology with key initiative of creating and validating key opinion leader mapping from over 200 healthcare professionals to 75.

Developed expert knowledge in Diabetes and Cardiovascular Disease for field medical activities in three new products. I created and validated a medical affairs impact profile for top 100 cardiologists and endocrinologists among hundreds for my territory.

Support the establishment of Diabetes and Cardiovascular portfolios through medical affairs activities and education initiatives for healthcare professionals. Responsible for aligning a set of collaborative strategic imperatives with commercial and market access colleagues on two drug launches.

Territory in the city of Toronto with coverage of over 150 primary care physicians. With established products, territory growth of 23% in CV and 9% in Allergy

Led the analysis of marketed and pipeline products in Cardiovascular Disease and Central Nervous System/Neuroscience. These scientific and financial analyst reports covered the US, European and Japanese markets.